NCI-H1618Homo sapiens (Human)Cancer cell line

Also known as: NCIH1618, H-1618, H1618

🤖 AI SummaryBased on 12 publications

Quick Overview

Human small cell lung cancer cell line with known RB1 mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H1618 cell line is a human small cell lung cancer (SCLC) cell line derived from a patient with extensive stage disease. It is characterized by the presence of mutations in the RB1 gene, which is a critical tumor suppressor involved in cell cycle regulation. These mutations contribute to the uncontrolled proliferation of cancer cells. The cell line has been utilized in various studies to investigate the molecular mechanisms underlying SCLC and to evaluate the efficacy of targeted therapies. Research has shown that NCI-H1618 exhibits sensitivity to certain chemotherapeutic agents, making it a valuable model for preclinical drug testing. Additionally, the cell line has been part of large-scale genomic and proteomic analyses to identify potential therapeutic targets and biomarkers for SCLC.

Research Applications

Molecular mechanisms of SCLCDrug sensitivity studiesTargeted therapy evaluationGenomic and proteomic analyses

Key Characteristics

RB1 mutationsExtensive stage disease originSensitivity to chemotherapeutic agents
Generated on 6/17/2025

Basic Information

Database IDCVCL_1480
SpeciesHomo sapiens (Human)
Tissue SourceBone marrow[UBERON:UBERON_0002371]

Donor Information

Age55
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeATCC
Source IDACH-000179_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg248Leu (c.743G>T)Unspecified-PubMed=18487078
MutationSimpleRB1p.Pro39Argfs*26 (c.116delC)Heterozygous-PubMed=30584916

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
9
D16S539
11,13
D18S51
15
D19S433
14,15
D21S11
27,31.2
D2S1338
23,24
D3S1358
15
D5S818
10
D7S820
8
D8S1179
11,14
FGA
22.2,24
Penta D
10,12
Penta E
16
TH01
6
TPOX
8,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Ihde D.C., Gazdar A.F.

J. Cell. Biochem. Suppl. 24:210-217(1996).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Linnoila R.I.

Oncogene 7:743-749(1992).

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

Gazdar A.F., Minna J.D.

Oncogene 7:339-346(1992).